Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Capital Expenditures (2018 - 2025)

Serina Therapeutics (SER) has disclosed Capital Expenditures for 6 consecutive years, with $13000.0 as the latest value for Q3 2025.

  • Quarterly Capital Expenditures rose 333.33% to $13000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $59000.0 through Dec 2025, up 168.18% year-over-year, with the annual reading at $59000.0 for FY2025, 168.18% up from the prior year.
  • Capital Expenditures hit $13000.0 in Q3 2025 for Serina Therapeutics, down from $46000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $119000.0 in Q3 2023 to a low of $3000.0 in Q3 2024.
  • Historically, Capital Expenditures has averaged $38571.4 across 3 years, with a median of $14000.0 in 2024.
  • Biggest five-year swings in Capital Expenditures: tumbled 97.48% in 2024 and later soared 333.33% in 2025.
  • Year by year, Capital Expenditures stood at $70000.0 in 2023, then crashed by 92.86% to $5000.0 in 2024, then skyrocketed by 160.0% to $13000.0 in 2025.
  • Business Quant data shows Capital Expenditures for SER at $13000.0 in Q3 2025, $46000.0 in Q2 2025, and $5000.0 in Q4 2024.